Diazoxide choline controlled release - Essentialis

Drug Profile

Diazoxide choline controlled release - Essentialis

Alternative Names: DCCR - Essentialis; Diazoxide choline

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Essentialis
  • Class Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Diagnostic agents; Peripheral vasodilators; Small molecules
  • Mechanism of Action KIR receptor modulators; Potassium channel agonists; Sulfonylurea receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Prader-Willi syndrome
  • No development reported Hypertriglyceridaemia
  • Discontinued Hypoglycaemia; Obesity

Most Recent Events

  • 27 Dec 2016 Essentialis plans a phase II/III trial for Prader-Willi syndrome in USA
  • 07 Sep 2016 Essentialis plans a phase II pharmacokinetics trial for Prader-Willi syndrome (In volunteers) in USA (PO) (NCT02893618)
  • 30 Aug 2016 Essentialis withdraws a phase I trial in Hypertriglyceridaemia (In volunteers) prior to enrolment in USA (PO) (NCT00901823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top